Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T16:13:10.851Z.
Calculation as of: 2026-10-06T16:13:10.851Z.
Quote observation: 2026-10-06T16:10:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a92f25166a0617989281a7eefd332dc08894ee274fcedbd674fe1a92e2c9d78d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$10.68M
EV/Sales Ratio
7639.79x
TTM Avg
8299.41x
3Y Avg
8299.41x
5Y Avg
8299.41x
Market Cap
$10.75M
EV/Sales Ratio
3.03x
TTM Avg
63.85x
3Y Avg
37.14x
5Y Avg
37.14x
Market Cap
$10.01M
EV/Sales Ratio
0.80x
TTM Avg
3.06x
3Y Avg
5.84x
5Y Avg
28.58x
Market Cap
$10.06M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.00M
EV/Sales Ratio
N/A
TTM Avg
30.14x
3Y Avg
54.00x
5Y Avg
56.96x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Satellos Bioscience Inc. (MSLE) | $10.45M | N/A | N/A | N/A | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.54M | N/A | N/A | N/A | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.68M | 7639.79x | 8299.41x | 8299.41x | 8299.41x |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.75M | 3.03x | 63.85x | 37.14x | 37.14x |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $10.01M | 0.80x | 3.06x | 5.84x | 28.58x |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $9.92M | 0.53x | 0.46x | 0.66x | 0.66x |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | 30.14x | 54.00x | 56.96x |
| BioVie Inc. (BIVI)vs › | $11.05M | N/A | N/A | N/A | N/A |
| Ainos, Inc. (AIMD)vs › | $9.76M | 1628.53x | 683.01x | 535.46x | 1037.99x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
